63 related articles for article (PubMed ID: 30102846)
1. Degradome of soluble ADAM10 and ADAM17 metalloproteases.
Scharfenberg F; Helbig A; Sammel M; Benzel J; Schlomann U; Peters F; Wichert R; Bettendorff M; Schmidt-Arras D; Rose-John S; Moali C; Lichtenthaler SF; Pietrzik CU; Bartsch JW; Tholey A; Becker-Pauly C
Cell Mol Life Sci; 2020 Jan; 77(2):331-350. PubMed ID: 31209506
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells.
Romero Y; Wise R; Zolkiewska A
Cancer Immunol Immunother; 2020 Jan; 69(1):43-55. PubMed ID: 31796994
[TBL] [Abstract][Full Text] [Related]
3. Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.
Dempsey PJ
Biochim Biophys Acta Mol Cell Res; 2017 Nov; 1864(11 Pt B):2228-2239. PubMed ID: 28739265
[TBL] [Abstract][Full Text] [Related]
4. Robo4 is constitutively shed by ADAMs from endothelial cells and the shed Robo4 functions to inhibit Slit3-induced angiogenesis.
Xiao W; Pinilla-Baquero A; Faulkner J; Song X; Prabhakar P; Qiu H; Moremen KW; Ludwig A; Dempsey PJ; Azadi P; Wang L
Sci Rep; 2022 Mar; 12(1):4352. PubMed ID: 35288626
[TBL] [Abstract][Full Text] [Related]
5. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.
Zocchi MR; Camodeca C; Nuti E; Rossello A; Venè R; Tosetti F; Dapino I; Costa D; Musso A; Poggi A
Oncoimmunology; 2016 May; 5(5):e1123367. PubMed ID: 27467923
[TBL] [Abstract][Full Text] [Related]
6. Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.
Hsia HE; Tüshaus J; Brummer T; Zheng Y; Scilabra SD; Lichtenthaler SF
Cell Mol Life Sci; 2019 Aug; 76(16):3055-3081. PubMed ID: 31236626
[TBL] [Abstract][Full Text] [Related]
7. A Disintegrin and metalloproteinase carves T cell abnormalities and pathogenesis in systemic lupus erythematosus.
Umeda M; Satyam A; Yoshida N; Kawakami A
Clin Immunol; 2024 May; 262():110168. PubMed ID: 38458301
[TBL] [Abstract][Full Text] [Related]
8. Roles for ADAM17 in TNF-R1 Mediated Cell Death and Survival in Human U937 and Jurkat Cells.
Fritsch J; Frankenheim J; Marischen L; Vadasz T; Troeger A; Rose-John S; Schmidt-Arras D; Schneider-Brachert W
Cells; 2021 Nov; 10(11):. PubMed ID: 34831323
[TBL] [Abstract][Full Text] [Related]
9. The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
Duffy MJ; Mullooly M; O'Donovan N; Sukor S; Crown J; Pierce A; McGowan PM
Clin Proteomics; 2011 Jun; 8(1):9. PubMed ID: 21906355
[TBL] [Abstract][Full Text] [Related]
10. Never say dye: new roles for an old fluorochrome.
Fotopoulos V
Plant Signal Behav; 2012 Mar; 7(3):342-4. PubMed ID: 22476459
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors.
Cuffaro D; Camodeca C; Tuccinardi T; Ciccone L; Bartsch JW; Kellermann T; Cook L; Nuti E; Rossello A
ACS Med Chem Lett; 2021 Nov; 12(11):1787-1793. PubMed ID: 35111280
[TBL] [Abstract][Full Text] [Related]
12. Development of a fluorogenic ADAMTS-7 substrate.
Santamaria S; Buemi F; Nuti E; Cuffaro D; De Vita E; Tuccinardi T; Rossello A; Howell S; Mehmood S; Snijders AP; de Groot R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2160-2169. PubMed ID: 34587841
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of ADAM10 reduce Hodgkin lymphoma cell growth in 3D microenvironments and enhance brentuximab-vedotin effect.
Pece R; Tavella S; Costa D; Varesano S; Camodeca C; Cuffaro D; Nuti E; Rossello A; Alfano M; D'Arrigo C; Galante D; Ravetti JL; Gobbi M; Tosetti F; Poggi A; Zocchi MR
Haematologica; 2022 Apr; 107(4):909-920. PubMed ID: 34109776
[TBL] [Abstract][Full Text] [Related]
14. Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease.
Kim N; Lee HJ
Biomed Res Int; 2020; 2020():2010728. PubMed ID: 33224974
[TBL] [Abstract][Full Text] [Related]
15. Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy.
Zocchi MR; Tosetti F; Benelli R; Poggi A
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32668783
[TBL] [Abstract][Full Text] [Related]
16. The metalloproteinase ADAM10 requires its activity to sustain surface expression.
Seifert A; Düsterhöft S; Wozniak J; Koo CZ; Tomlinson MG; Nuti E; Rossello A; Cuffaro D; Yildiz D; Ludwig A
Cell Mol Life Sci; 2021 Jan; 78(2):715-732. PubMed ID: 32372373
[TBL] [Abstract][Full Text] [Related]
17. Specific ADAM10 inhibitors localize in exosome-like vesicles released by Hodgkin lymphoma and stromal cells and prevent sheddase activity carried to bystander cells.
Tosetti F; Venè R; Camodeca C; Nuti E; Rossello A; D'Arrigo C; Galante D; Ferrari N; Poggi A; Zocchi MR
Oncoimmunology; 2018; 7(5):e1421889. PubMed ID: 29721369
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.
Camodeca C; Nuti E; Tosetti F; Poggi A; D'Arrigo C; Zocchi MR; Rossello A
ChemMedChem; 2018 Oct; 13(19):2119-2131. PubMed ID: 30102846
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
